Page 2 - Aipsc News Today

Century Therapeutics (NASDAQ:IPSC – Get Free Report) had its price target reduced by research analysts at HC Wainwright from $17.00 to $13.00 in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target suggests a potential upside of 364.29% […]

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) have earned an average recommendation of “Buy” from the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued ratings on the stock […]

Shares of Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) have earned an average rating of “Buy” from the ten research firms that are covering the company, Marketbeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 1-year target price among analysts that have issued ratings on the stock in the last […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) has been assigned an average rating of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1 year target price among analysts […]

EF Hutton Acquisition Co. I restated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research report report published on Monday morning, Benzinga reports. EF Hutton Acquisition Co. I currently has a $16.00 target price on the stock. IPSC has been the topic of several other reports. Chardan Capital restated […]

EF Hutton Acquisition Co. I reissued their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $16.00 price target on the stock. Other analysts also recently issued reports about the company. SVB Leerink reduced their price objective […]

HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research report report published on Thursday, Benzinga reports. They currently have a $17.00 target price on the stock. Other equities research analysts have also recently issued research reports about the company. Chardan Capital restated a buy rating and […]

HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a report issued on Thursday, Benzinga reports. HC Wainwright currently has a $17.00 price objective on the stock. Several other research firms have also recently commented on IPSC. Piper Sandler decreased their price target on shares of Century Therapeutics […]

HC Wainwright reaffirmed their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a $17.00 price target on the stock. IPSC has been the topic of a number of other research reports. Bank of America dropped their price objective on […]

Century Therapeutics (NASDAQ:IPSC – Get Rating)‘s stock had its “buy” rating reaffirmed by research analysts at EF Hutton Acquisition Co. I in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $16.00 target price on the stock. EF Hutton Acquisition Co. I’s target price points to a potential […]